IP Library Granted Patent US 10,584,314
Granted Patent B2
US 10,584,314 · App. 15/502,321 · Granted Mar 10, 2020

Method for preparation of retinal ganglion cells

Inventors: Noriyuki Azuma (Tokyo, JP); Taku Tanaka (Tokyo, JP); Tadashi Yokoi (Tokyo, JP)
Assignees: NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT; SENJU PHARMACEUTICAL CO., LTD.
C12N5/0621A61K35/30A61L27/00A61P27/06C12N15/09C12Q1/02C12Q1/6876G01N33/5058C12N2501/13C12N2506/02C12N2506/08C12N2506/45C12Q2600/136C12Q2600/158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,584,314
App. No.
15/502,321
Granted
Mar 10, 2020
Kind
B2
Abstract

An object of the present invention is to provide a method of inducing pluripotent stem cells to differentiate into clinically applicable retinal ganglion cells. The present invention provides a method for inducing pluripotent stem cells to differentiate into retinal ganglion cells that can be used for clinical application. Such method is a method for producing retinal ganglion cells with elongated axons comprising the following steps: (a) a step of inducing pluripotent stem cells to differentiate into retinal progenitor cells via floating culture; (b) a step of inducing the retinal progenitor cells obtained in step (a) to differentiate into retinal ganglion cells via floating culture; and (c) a step of allowing axons to elongate via adhesion culture of the retinal ganglion cells obtained in step (b).

Claims (7)

1. A method for producing retinal ganglion cells with elongated axons comprising:

(a) subjecting pluripotent stem cells to floating culture to induce differentiation into retinal progenitor cells by floating culture;

(b) subjecting the retinal progenitor cells obtained in step (a) to floating culture to induce differentiation into retinal ganglion cells by floating culture; and

(c) allowing axons to elongate by adhesion culture of the retinal ganglion cells obtained in step (b).

2. The method according to claim 1 , wherein the pluripotent stem cells are induced pluripotent stem cells (iPS cells) or embryonic stem cells (ES cells).

3. The method according to claim 1 , wherein the adhesion culture is done in a medium containing neurotrophic factors.

4. The method according to claim 1 , wherein the adhesion culture is done in a medium wherein the surface level of the medium is the same height or lower than the height of the cell mass adhered to the culture vessel.

Assignments (2)
CHANGE OF ADDRESS Recorded Aug 24, 2018
From: SENJU PHARMACEUTICAL CO., LTD.
To: SENJU PHARMACEUTICAL CO., LTD.
Reel/Frame 046835/0350 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2017
From: AZUMA, NORIYUKI; TANAKA, TAKU; YOKOI, TADASHI
To: NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT; SENJU PHARMACEUTICAL CO., LTD.
Reel/Frame 041193/0334 →
Priority Claims (2)
JP 2014-162370 · Aug 8, 2014 · national
JP 2014-230157 · Nov 12, 2014 · national
Continuity (1)
Related Publication 20170191033A1 · Jul 6, 2017